Evidence map›Paper›PMID 11559821›Full record

ArticleJournal of virology2001

Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300.

W Zhang, J W Nisbet, B Albrecht, W Ding, F Kashanchi, J T Bartoe, M D Lairmore

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 88 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Regulation of HTLV-1 transformation.Bioscience reports · 2022
    Review
  6. Mechanisms of Oncogenesis by HTLV-1 Tax.Pathogens (Basel, Switzerland) · 2020
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

W ZhangCenter for Retrovirus Research and Department of Veterinary Biosciences, The Arthur James Cancer Hospital and Research Institute, The Ohio State University, Columbus, Ohio 43210, USA.
J W Nisbet
B Albrecht
W Ding
F Kashanchi
J T Bartoe
M D Lairmore
Cancer Hospital and Research Institute · INGeorge Washington University · US

Funding

ANIMAL MODELS OF MOLECULAR PATHOGENSIS OF HTLV-1R01RR014324 · NCRR · OHIO STATE UNIVERSITY · PI LAIRMORE, MICHAEL D · 1999 to 2003
$1.2M
CRE-MEDIATED TRANSCRIPTION IN PRIMARY T LYMPHOCYTESK02AI001474 · NIAID · OHIO STATE UNIVERSITY · PI LAIRMORE, MICHAEL D · 1997 to 2001
$200k
TRAINING IN MOLECULAR VIROLOGY AND HTLV-1 PATHOGENESISK08CA070259 · NCI · OHIO STATE UNIVERSITY · PI COLLINS, NATHANIEL D · 1997 to 1998
–
NCI NIH HHS CA-70259NCRR NIH HHS R01 RR014324NCRR NIH HHS RR-14324NIAID NIH HHS K02 AI01474
6 · The paper itself

Abstract

The highly conserved coadapters CREB binding protein (CBP) and p300 form complexes with CREB as well as other DNA binding transcription factors to modulate chromatin remodeling and thus transcription. Human T-lymphotropic virus type 1 (HTLV-1) transcription is controlled, in part, by the CREB/ATF family of transcription factors which bind promoter sequences and function as complexes with the viral oncogenic protein Tax. We have reported that the nuclear localizing protein p30(II) of HTLV-1 functions as a transcription factor, differentially modulates CREB-responsive promoters, and is critical for maintenance of proviral loads in rabbits. In this study, we tested whether p30(II) directly interacts with CBP/p300 to modulate gene transcription. Gal4(BD)-p30(II)-mediated transactivation was enhanced following exogenous expression of p300 and was competitively repressed by the p300 binding protein, adenovirus E1A, and E1ACR2 (mutated for retinoblastoma binding but retaining p300 binding). In contrast, E1ACR1 (mutated for p300 binding) failed to alter Gal4(BD)-p30(II)-mediated transactivation. In addition, Gal4(BD)-p30(II)-mediated transactivation was competitively inhibited by the cotransfection of CMV-p30(II)-HA and CMV-Tax but could be rescued by exogenous p300. Importantly, we demonstrate that p30(II) colocalizes with p300 in cell nuclei and directly binds to CBP/p300 in cells. Deletion mutants of CBP/p300 were used to localize the site critical for binding p30(II) to a highly conserved KIX region. DNA binding assays confirmed the interference of p30(II) with the assembly of CREB-Tax-p300/CBP multiprotein complexes on 21-bp repeat oligonucleotides in vitro. Collectively, our results demonstrate that CBP/p300 is a cellular protein target for HTLV-1 p30(II) and mediates its transcriptional effects in vivo.

Indexed as

Transcription, GeneticAdenovirus E1A ProteinsCell LineCyclic AMP Response Element-Binding ProteinHumansHuman T-lymphotropic virus 1MutationNuclear ProteinsProtein BindingRetroviridae ProteinsTrans-ActivatorsAdenovirus E1A ProteinsCyclic AMP Response Element-Binding ProteinNuclear ProteinsRetroviridae Proteinstof protein, Human T-lymphotropic virus 1Trans-Activators

Identifiers

PMID11559821
PMCPMC114560
OpenAlexW2115344912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.